Onconova On The Edge After Phase III Rigosertib MDS Failure
Switch To Oral Version But Not For MDS
Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.
You may also be interested in...
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.